December 20, 2017 / 11:29 PM / 10 months ago

BRIEF-Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc:

* APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2

* APELLIS PHARMACEUTICALS INC - PHASE 3 PROGRAM EVALUATING APL-2 PLANNED TO BEGIN IN SECOND HALF OF 2018

* APELLIS PHARMACEUTICALS - PHASE 3 PROGRAM TO CONSIST OF TWO IDENTICAL 600-PATIENT STUDIES TO ASSESS EFFICACY,SAFETY

* APELLIS PHARMACEUTICALS INC - PHASE 3 TRIALS EVALUATING APL-2 WILL BE SUBSTANTIALLY SIMILAR IN DESIGN TO APELLIS’ ONGOING PHASE 2 FILLY TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below